Drug intelligence / Profile preview

siRNA (GAL-3)

Development stage
Preclinical
Lead developer
Inserm
Modality
Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration
Subcutaneous
01

Overview

siRNA (GAL-3) refers to small interfering RNA molecules designed to specifically silence the expression of Galectin-3 (encoded by the LGALS3 gene). Galectin-3 is a beta-galactoside-binding protein involved in various cellular processes, including cell growth, adhesion, and apoptosis. In the context of oncology, particularly glioblastoma, GAL-3 is often overexpressed and associated with tumor progression and resistance to therapy. By targeting GAL-3 mRNA for degradation, these siRNAs reduce GAL-3 protein levels, which has been shown in preclinical models to inhibit glioblastoma stem cell proliferation, induce cell cycle arrest in the G1 phase, and enhance the sensitivity of tumor cells to chemotherapeutic agents like temozolomide.

Other names
LGALS3 siRNALGALS-3 siRNALGALS 3 siRNAGalectin-3 siRNAGalectin3 siRNAGalectin 3 siRNA
02

Targets

LGALS3 (Galectin-3)Galectin-3 messenger RNA (LGALS3 mRNA)

Beyond the preview

Go deeper on siRNA (GAL-3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on siRNA (GAL-3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call